Modality
Multispecific
MOA
KRASG12Di
Target
CD3
Pathway
Amyloid
PsA
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
~Aug 2017
→ ~Nov 2018
Phase 3
Feb 2019
→ Apr 2029
Phase 3Current
NCT04132459
1,143 pts·PsA
2019-02→2029-04·Recruiting
NCT03334580
1,846 pts·PsA
2022-09→2028-05·Recruiting
NCT07719303
282 pts·PsA
2024-11→TBD·Active
3,271 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-032.1y awayPh3 Readout· PsA
2029-04-093.0y awayPh3 Readout· PsA
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Recruit…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2028-05-03 · 2.1y away
PsA
Ph3 Readout
2029-04-09 · 3.0y away
PsA
RecruitingActive|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04132459 | Phase 3 | PsA | Recruiting | 1143 | PANSS |
| NCT03334580 | Phase 3 | PsA | Recruiting | 1846 | EFS |
| NCT07719303 | Phase 3 | PsA | Active | 282 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |